Deals of the Week: Aptalis For Sale
A report suggests that Aptalis Pharma is on the block, but is the price too high? Also, Quintiles spends some of its IPO war chest on a smaller North Carolina CRO, and Pfizer strikes a diabetes deal with Sanford-Burnham.
You may also be interested in...
Bad press and lawsuits related to bleeding events for Boehringer Ingelheim’s novel anticoagulant Pradaxa create a window of opportunity for Eliquis, which is pending approval in the U.S. and could have what it takes to tip the market away from generic warfarin.
Data from the pilot program a “driving factor” in the agency’s decision against changing its recommendations for the blood thinner following reports of increased serious bleeding events.
Par will be acquired by private equity firm TPG in $1.9 billion deal if no other suitors come forward with a better offer over the next month.